We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Bayer beware

1 October 2015 By Olaf Storbeck

The German drug giant has slashed the size of its plastics arm’s listing by 40 pct and cut the price by a quarter, blaming China and VW woes. As the proceeds will be used to lower its own debt, its balance sheet will be weaker than it could have been. Bayer should have waited.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)